ADRB2 and ovarian carcinoma: Our lab and others have previously shown that non-selective β-AR antagonists are superior to selective β-AR antagonists with regard to decreasing tumor cell proliferation and enhancing clinical outcome in breast, liver, and ovarian cancer [15, 57, 58].